Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Evotec AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

22 Aug 2015 Reuters Investment Profile 12 $20.00

ValuEngine Industry Report for Medical-Drugs(EVTCY)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

26 Aug 2015 ValuEngine, Inc. 10 $49.00

ValuEngine Rating and Forecast Report for EVTCY

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

22 Aug 2015 ValuEngine, Inc. 11 $25.00

Q2/15 mit sehr guter EVT Execute Entwicklung - auch Sanofi-Deal als Treiber

Unsere Erwartung deutlich steigender Erlöse im Basisgeschäft (EVT Execute, EXE) wurde im H1/15 nicht enttäuscht. Die Ausweitu...

21 Aug 2015 EQUI.TS 4 $10.00

Is Evotec AG a Good Long-Term Investment?

19 Aug 2015 Sadif Analytics Prime 12 $25.00

Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review

Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review Summary Evotec AG (Evotec) is a drug discovery alliance and de...

18 Aug 2015 GlobalData 65 $125.00

Wright Investors Service Comprehensive Report for Evotec AG

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

13 Aug 2015 Wright Reports 56 $75.00

ValuEngine Industry Report for Medical-drugs(EVTCY)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

22 Jul 2015 ValuEngine, Inc. 10 $49.00

EVT302 ohne Wirksamkeit, umso wichtiger werden operative Fortschritte - 2015 startet erfreulich

Enttäuschung: Die Phase 2b Tests des Alzheimer Wirkstoffs EVT302 zeigte keine Wirksamkeit; so Partner Roche am 30.6.15. Der E...

07 Jul 2015 EQUI.TS 4 $10.00

EVOTEC - GROWTH DRIVERS INTACT DESPITE EVT302 SETBACK

EVT302 has failed to meet the primary endpoint of a Phase IIb trial in Alzheimer’s disease. Partner Roche will now fully eva...

02 Jul 2015 Edison Investment Research 4 $10.00